CN Patent

CN117460509B — 作为c-Met激酶抑制剂的化合物治疗I型神经纤维瘤病的用途

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2025-03-28 · 1y expired

What this patent protects

c‑Met激酶抑制剂的化合物制备治疗I型神经纤维瘤病药物的用途，具体涉及N‑(4‑((7‑((1‑(环戊烷基氨基)环丙烷基)甲氧基)‑6‑甲氧基喹诺林‑4‑基)氧基)‑3‑氟苯基)‑N‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺制备治疗I型神经纤维瘤病药物的用途和方法。

USPTO Abstract

c‑Met激酶抑制剂的化合物制备治疗I型神经纤维瘤病药物的用途，具体涉及N‑(4‑((7‑((1‑(环戊烷基氨基)环丙烷基)甲氧基)‑6‑甲氧基喹诺林‑4‑基)氧基)‑3‑氟苯基)‑N‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺制备治疗I型神经纤维瘤病药物的用途和方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117460509B
Jurisdiction
CN
Classification
—
Expires
2025-03-28
Drug substance claim
No
Drug product claim
No
Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.